Emiel A. M. Janssen

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

Hans Petter Eikesdal, Synnøve Yndestad, Ahmed El‐Zawahry et al. · Annals of Oncology · 2020 · 210 citations · Full text

De-novo mutation in hereditary motor and sensory neuropathy type I

Jessica E. Hoogendijk, Gerard W. Hensels, Emiel A. M. Janssen et al. · The Lancet · 1992 · 161 citations

Rare Diseases, Hereditary Motor, Mendelian Disorder +10

Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer

Einar Gudlaugsson, Ivar Skaland, Emiel A. M. Janssen et al. · Histopathology · 2012 · 128 citations

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Prospective Multicenter Validation of the Independent Prognostic Value of the Mitotic Activity Index in Lymph Node–Negative Breast Cancer Patients Younger Than 55 Years

Jan P. A. Baak, P. J. van Diest, Feja J. Voorhorst et al. · Journal of Clinical Oncology · 2005 · 112 citations